Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06112990 · ClinicalTrials.gov registry record · Phase 3
Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression
A Phase 3 study of Metastatic Prostate Cancer, sponsored by University of Utah.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06112990: Recruiting Phase 3 study of Metastatic Prostate Cancer, sponsored by University of Utah.
NCT06112990 is a Phase 3 study of Metastatic Prostate Cancer that is actively recruiting participants, run by University of Utah. The registered enrollment target is 200 participants, above the 182-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (10% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06112990, a Phase 3 study of Metastatic Prostate Cancer, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to test the use of creatine monohydrate supplementation with resistance training to preserve muscle mass and help lessen prostate cancer progression. The main question it aims to answer is if this treatment will help maintain muscle mass to help in reducing fatigue and improving physical function, independence, and quality of life. Participants will be asked to participate in a 52-week exercise intervention consisting of a twice weekly telehealth resistance training program.
Primary Outcome
To test the efficacy of 52-weeks of home-based, telehealth resistance training (RT) with creatine monohydrate supplementation (Cr) or placebo (PLA), Cr+RT vs. PLA+RT, on changes in muscle mass in metastatic castration sensitive prostate cancer survivors receiving androgen deprivation therapy (n=200).
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT creatine monohydrate
- BEHAVIORAL Home-based, telehealth
Study Locations (1)
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2028-11-30 |
| Phase | Phase 3 |
What NCT06112990 shows while recruiting
NCT06112990 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 182-participant average among 41 other Metastatic Prostate Cancer trials with a reported enrollment target (10% higher).
The record links to 1 condition, with Metastatic Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06112990 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT06112990 about?
NCT06112990 is a clinical study titled "Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression". The goal of this clinical trial is to test the use of creatine monohydrate supplementation with resistance training to preserve muscle mass and help lessen prostate cancer progression. The main question it aims to answer is if this treatment will help maintain muscle mass to help in reducing fatigu...
What is the current status of trial NCT06112990?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2023-11-09. Estimated completion is 2028-11-30.
What conditions does trial NCT06112990 study?
This clinical trial studies the following conditions: Metastatic Prostate Cancer.
What interventions are being tested in trial NCT06112990?
The interventions under investigation include: Placebo (OTHER), creatine monohydrate (DIETARY_SUPPLEMENT), Home-based, telehealth (BEHAVIORAL).
Who is sponsoring clinical trial NCT06112990?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06112990 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06112990's enrollment target sits among peer trials
200 10th of 41 higher than 32 of 41 other Metastatic Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
ACTIVE NOT RECRUITING · Phase 3
-
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
COMPLETED · Phase 3
-
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
COMPLETED · Phase 3
-
Impact of Multimodal Telerehabilitation in Rural Patients With Metastatic Prostate Cancer
RECRUITING · NA
-
Study of AZD0754 in Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI